In adults with type 2 diabetes, total body BMD change from baseline at 52 or 104 weeks did not differ between liraglutide 1.2 or 1.8 mg/day and glimepiride 8 mg/day.
In plain wordsIn adults with type 2 diabetes, liraglutide did not change bone density differently from glimepiride over two years.
- Peptide
- Liraglutide
- Outcome
- No significant changeChange in total body BMD at 52 and 104 weeks
- Study
n = 61
- Comparator
- Glimepiride 8 mg/day
- Analysis
- Primary
- Outcome group
- Bone and joint · Musculoskeletal
- Studied dose
- 1.2 and 1.8 mg/day · 104 weeksAs given in this study (human).
Source sentences
There was no apparent difference in mean total BMD change from baseline in patients receiving liraglutide 1.8 or 1.2 mg/day or glimepiride 8 mg/day at 52 or 104 weeks.
2 context sentences(design, population, supporting numbers)
LEAD-3, a 52-week, double-blind, active-control, phase III, multicenter trial, investigated the efficacy of liraglutide (1.2 and 1.8 mg/day) versus glimepiride monotherapy in type 2 diabetes.
Of these, 61 patients (20 assigned to liraglutide 1.8 mg/day, 23 to liraglutide 1.2 mg/day, 18 to glimepiride 8 mg/day) had BMD measurements.